Literature DB >> 30269188

The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis.

Elena Bargagli1, Maria Di Masi2, Marco Perruzza3, Lucia Vietri3, Laura Bergantini3, Elena Torricelli2, Giulia Biadene2, Giovanni Fontana2, Federico Lavorini2.   

Abstract

Idiopathic pulmonary fibrosis is a peripheral subpleural interstitial lung disorder limited to the lung not involving the airways. It has a poor prognosis (survival less than 5 years) and commonly an interstitial pneumonia radiological pattern. Patients complain of a chronic dry cough in 80% of cases. A cough is often the first symptom of this rare disease, preceding dyspnea by years, and is associated with a poor prognosis, high dyspnea scores and low FVC percentages. The pathogenetic mechanisms leading to coughing in IPF are unclear. This review focuses on recent evidence of cough pathophysiology in this disease. Gastroesophageal reflux may promote coughing in IPF patients; bile salts and pepsin may be abundant in BAL of these patients, inducing overproduction of TGF-β by airway epithelial cells and mesenchymal transition with fibroblast recruitment/activation and extracellular matrix deposition. Patients have an enhanced cough reflex to capsaicin and substance P with respect to control subjects. Moreover, patients with the MUC5B polymorphism show more severe coughing as MUC5B encodes for the dominant mucin in the honeycomb cysts of IPF patients. Comorbidities, including asthma, gastroesophageal reflux, hypersensitivity pneumonitis, bronchiectasis, chronic obstructive pulmonary disease and emphysema, can induce coughing in IPF patients. There is no clear explanation of the causes of coughing in IPF. Further research into the pathophysiology of IPF and the pathogenetic mechanisms of coughing is necessary to improve survival and quality of life.

Entities:  

Keywords:  Cough; Idiopathic pulmonary fibrosis; Pathogenesis

Mesh:

Year:  2018        PMID: 30269188     DOI: 10.1007/s11739-018-1960-5

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  7 in total

1.  Mechanism of miR-204-5p in exosomes derived from bronchoalveolar lavage fluid on the progression of pulmonary fibrosis via AP1S2.

Authors:  Liang Zhu; Yahui Chen; Mo Chen; Wenwen Wang
Journal:  Ann Transl Med       Date:  2021-07

2.  Clinical significance of self-reported cough intensity and frequency in patients with interstitial lung disease: a cross-sectional study.

Authors:  Ryuhei Sato; Tomohiro Handa; Hisako Matsumoto; Takeshi Kubo; Toyohiro Hirai
Journal:  BMC Pulm Med       Date:  2019-12-16       Impact factor: 3.317

3.  Management of cough in patients with idiopathic interstitial lung diseases in primary care.

Authors:  Diana C Sanchez-Ramirez; Leanne Kosowan; Alex Singer
Journal:  Chron Respir Dis       Date:  2022 Jan-Dec       Impact factor: 2.444

Review 4.  Cough in Idiopathic Pulmonary Fibrosis.

Authors:  Jennifer Mann; Nicole S L Goh; Anne E Holland; Yet Hong Khor
Journal:  Front Rehabil Sci       Date:  2021-10-18

Review 5.  Management of musculoskeletal pain in patients with idiopathic pulmonary fibrosis: a review.

Authors:  Svetlana Kašiković Lečić; Jovan Javorac; Dejan Živanović; Aleksandra Lovrenski; Dragana Tegeltija; Jelena Zvekić Svorcan; Jadranka Maksimović
Journal:  Ups J Med Sci       Date:  2022-07-11       Impact factor: 2.646

6.  Salivary Pepsin as an Intrinsic Marker for Diagnosis of Sub-types of Gastroesophageal Reflux Disease and Gastroesophageal Reflux Disease-related Disorders.

Authors:  Yan-Jun Wang; Xiu-Qiong Lang; Dan Wu; Yu-Qin He; Chun-Hui Lan; Xiao Xiao; Bin Wang; Duo-Wu Zou; Ji-Min Wu; Yong-Bin Zhao; Peter W Dettmar; Dong-Feng Chen; Min Yang
Journal:  J Neurogastroenterol Motil       Date:  2020-01-30       Impact factor: 4.924

7.  Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases.

Authors:  Laura Bergantini; Miriana d'Alessandro; Lucia Vietri; Giuseppe Domenico Rana; Paolo Cameli; Silvia Acerra; Piersante Sestini; Elena Bargagli
Journal:  Immunol Res       Date:  2020-10-22       Impact factor: 2.829

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.